Emergent BioSolutions Inc.
EBS NYSE· Pharmaceutical Preparations
Last close · Oct 26, 2026
$6.34
KIRA · Stoqly’s AI analyst, in plain words
- Emergent BioSolutions Inc. had $743M of revenue in fiscal 2025, down 28.8% on the year before. Over five years, revenue changed −14.0% a year on average.
- Its operating margin was 13.5%, up 23.9 pts: of every 100 in sales, about 13 is left after running the business.
- Emergent BioSolutions Inc. made $52.6M of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew −2.1% a year.
- Free cash flow was $157M in fiscal 2025, 21.1% of revenue.
- Emergent BioSolutions Inc. returned $24.9M to shareholders in fiscal 2025, 16% of free cash flow. The diluted share count rose 7.0%.
- Emergent BioSolutions Inc. owes $384M more than it holds in cash, about 2.0 years of operating profit.
Market cap
$327M
P/E
—
Revenue
$743M
Net income
$52.6M
Free cash flow
$157M
Operating margin
13.5%
Emergent BioSolutions Inc. in 30 seconds · fiscal 2025
Are sales growing?
−28.8%
No. Sales fell 28.8% last year.
Does it make a profit?
7.1%
A little. It keeps 7.1% of every sale as profit.
Does profit turn into cash?
21.1%
Yes. 21.1% of sales ends up as free cash.
Is debt under control?
2.0x
Keep an eye on it. Repaying its debt would take 2.0 years of operating profit.
How healthy are the accounts?
7 / 9
Solid. It passes 7 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Emergent BioSolutions Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 27, 2026
- Legal name
- Emergent BioSolutions Inc.
- CIK
- 0001367644
Emergent BioSolutions Inc. · EBS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.8B | $1.1B | $1.0B | $1.0B | $743M |
| Revenue growth | 12.4% | −37.0% | −6.1% | −0.5% | −28.8% |
| Gross margin | 50.3% | 34.3% | 30.3% | 34.7% | 56.1% |
| Operating margin | 19.2% | −15.2% | −69.2% | −10.4% | 13.5% |
| Net income | $220M | −$212M | −$761M | −$191M | $52.6M |
| Net margin | 12.4% | −18.9% | −72.5% | −18.3% | 7.1% |
| Diluted EPS | $4.06 | −$4.22 | −$14.85 | −$3.60 | $0.93 |
| Cash | |||||
| Cash from operations | $320M | −$34.1M | −$206M | $58.7M | $171M |
| Capital expenditure | $224M | $116M | $51.6M | $22.9M | $13.8M |
| Free cash flow | $96.1M | −$150M | −$258M | $35.8M | $157M |
| FCF margin | 5.4% | −13.4% | −24.6% | 3.4% | 21.1% |
| Share buybacks | $106M | $82.1M | $0.0M | $0.0M | $24.9M |
| Share count change | 0.6% | −7.4% | 2.2% | 3.5% | 7.0% |
| Debt and strength | |||||
| Cash and short-term investments | $576M | $643M | $112M | $99.5M | $205M |
| Debt incl. finance leases | $850M | $1.4B | $868M | $700M | $590M |
| Shareholders' equity | $1.6B | $1.4B | $649M | $483M | $523M |
| Net debt / EBITDA | 0.6x | — | — | 6,005.0x | 2.0x |
| Current ratio | 3.4x | 1.0x | 1.0x | 3.7x | 5.0x |
| Interest coverage | 9.9x | −4.6x | −8.3x | −1.5x | 1.7x |
| Returns and quality | |||||
| Return on capital | 13.1% | −6.2% | −40.8% | −7.9% | 7.2% |
| Return on equity | 14.3% | −14.1% | −74.7% | −33.7% | 10.5% |
| Return on tangible equity | 28.1% | −48.0% | −919.6% | — | 61.1% |
| Piotroski F-score | 6 | 2 | 3 | 6 | 7 |
| Altman Z'' | 5.1 | 1.2 | −2.0 | 1.6 | 3.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$1.3M
6 insiders
Of sales under plans
79%
$1.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Emergent BioSolutions Inc. · EBS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.34 a share, the company is worth $327M.
Source: SEC EDGAR XBRL filings (CIK 0001367644). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.